Dr. Sarah Glass is a molecular geneticist and biotechnology leader dedicated to transforming the future of precision medicine for the nano-rare disease community. As Chief Operating Officer at the n-Lorem Foundation, she oversees the development and delivery of individualized antisense oligonucleotide (ASO) therapies designed specifically for patients with ultra-rare genetic mutations. Before joining n-Lorem, Dr. Glass served as Global Head of Rare Diseases at Parexel and held senior roles at Teva Pharmaceuticals and GlaxoSmithKline, where she built genomic medicine programs integrating human genetics into clinical development. Motivated by her personal journey as the parent of a child with a nano-rare condition, Dr. Glass combines scientific expertise with deep empathy for the patients and families she serves. Her leadership has helped establish n-Lorem as a global innovator, proving that individualized medicines can be both scientifically rigorous and profoundly humane.

We cannot do
this alone

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.